

IN THE CLAIMS:

Please enter any changes in the claims indicated in the complete copy of the pending claims, as sought to be amended, presented below:

1-16. (Canceled).

17. (New) An improved solid pharmaceutical dosage formulation of a hydrophobic drug, comprising:

an ingestible base substrate comprising a first polymer;
a deposit, comprising a therapeutic amount of a hydrophobic drug, deposited on the base substrate, wherein the deposit is essentially free of surfactant;
an ingestible cover substrate comprising a second polymer, the cover substrate covering the deposit and joined to the base substrate by a bond that surrounds the deposit; and
a dissolution-enhancing amount of a surfactant, disposed within a carrier that is segregated from, but in contact with, the deposit, wherein one or more of the following applies,
the carrier, comprising ingestible material, is distinct from the cover substrate and the base substrate, or
the carrier is an ingestible adhesive layer, or
the surfactant is not a polyoxyethylene sorbitan mono-oleate.

18. (New) The dosage formulation of claim 17, wherein the base substrate comprises a planar film.

19. (New) The dosage formulation of claim 18, wherein the base substrate film has a shape comprising a semi-spherical bubble, wherein the deposit is disposed within the perimeter of the semi-spherical bubble.

20. (New) The dosage formulation of claim 17, wherein the cover substrate comprises a planar film.

21. (New) The dosage formulation of claim 20, wherein the cover substrate film has a shape comprising a semi-spherical bubble, wherein the deposit is disposed within the perimeter of the semi-spherical bubble.

22. (New) The dosage formulation according to claim 17, wherein the deposit has a shape that is substantially circular, and the deposit has a diameter in the range of about 3 millimeters to about 7 millimeters.

23. (New) The dosage formulation according to claim 17, wherein the first polymer or second polymer comprises a thermoplastic material.

24. (New) The dosage formulation according to claim 17, wherein the first polymer or second polymer is selected from the group consisting of polymers and copolymers of polyvinyl alcohol, polyvinyl pyrrolidinone, polysaccharide polymers, acrylate polymers, methacrylate polymers, phthalate polymers, polyvinyl acetate, methyl cellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethyl cellulose, polyethylene oxide, polypropylene, polyester and polyamide films, Eudragits, starch-based polymers and gelatin.

25. (New) The dosage formulation according to claim 17, wherein the first polymer and the second polymer are the same.

26. (New) The dosage formulation according to claim 17, wherein the carrier is the cover substrate.

27. (New) The dosage formulation according to claim 17, wherein the carrier is an ingestible adhesive that is applied to the cover substrate.

28. (New) The dosage formulation according to claim 17, wherein the carrier is a pouch, disposed between the deposit and the cover substrate, the pouch comprising an ingestible material.

29. (New) The dosage formulation according to claim 17, wherein the hydrophobic drug is deposited electrostatically.

30. (New) An improved solid pharmaceutical dosage formulation, comprising:
an ingestible base substrate comprising a first polymer;
a deposit, comprising a therapeutic amount of a drug, deposited on the base substrate;
an ingestible cover substrate comprising a second polymer, the cover substrate covering the deposit and joined to the base substrate by a bond that surrounds the deposit; and
a pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit, wherein one or more of the following applies,
the carrier, comprising ingestible material, is distinct from the cover substrate and the base substrate, or
the carrier is an ingestible adhesive layer, or
the surfactant is not a polyoxyethylene sorbitan mono-oleate,
wherein the deposit is essentially free of the additive.

31. (New) The dosage formulation according to claim 29, wherein the drug is deposited electrostatically.